GLP-1 Receptor Agonists Comparison — Semaglutide vs Tirzepatide vs Retatrutide

GLP-1 Receptor Agonists: Semaglutide vs Tirzepatide vs Retatrutide

The GLP-1 receptor agonist class has seen rapid evolution, from single-agonist molecules to dual and triple agonists. This research comparison examines three key compounds — semaglutide (single GLP-1), tirzepatide (dual GLP-1/GIP), and retatrutide (triple GLP-1/GIP/glucagon) — covering their molecular differences, receptor pharmacology, and research applications.

Comparative Overview

Receptor Pharmacology

GLP-1 Receptor (GLP-1R)

All three compounds activate the GLP-1 receptor, which is the primary mechanism for glucose-dependent insulin secretion, appetite regulation via hypothalamic signaling, gastric emptying delay, and beta-cell preservation and proliferation.

GIP Receptor (GIPR)

Tirzepatide and retatrutide additionally activate GIP receptors. GIP receptor activation enhances insulin secretion synergistically with GLP-1, may improve lipid metabolism, potentially contributes to central appetite regulation, and plays roles in bone metabolism and adipose tissue function.

Glucagon Receptor (GCGR)

Retatrutide uniquely activates the glucagon receptor. Glucagon receptor agonism increases energy expenditure via thermogenesis, promotes hepatic lipid oxidation, enhances amino acid catabolism, and may contribute to additional weight reduction beyond GLP-1/GIP effects.

Research Highlights

Semaglutide Research

As the most established compound, semaglutide has extensive preclinical and clinical research data. Key findings include demonstrated cardiovascular risk reduction in SUSTAIN and SELECT trials, effective weight reduction of 15-17% in STEP trials, neuroprotective effects being explored in Alzheimer’s research, and oral formulation (Rybelsus) demonstrating feasibility of oral peptide delivery.

Tirzepatide Research

The dual GLP-1/GIP agonist approach has shown enhanced efficacy in SURPASS and SURMOUNT trials with weight reduction of 20-25%, superior glycemic control compared to semaglutide in head-to-head trials, improved lipid profiles beyond GLP-1-only effects, and potential applications in NASH/MAFLD research.

Retatrutide Research

As the first triple agonist, retatrutide represents the cutting edge of incretin research. Phase 2 data showed unprecedented weight reduction of up to 24% at 48 weeks, significant reduction in liver fat content, dose-dependent efficacy with manageable GI side effects, and the additional glucagon activity contributing to enhanced energy expenditure.

Research Compounds from Aarise Healthcare

Aarise Healthcare supplies research-grade semaglutide, tirzepatide, and retatrutide for qualified research institutions. All compounds are verified ≥98% purity by HPLC with full characterization documentation. Browse our GLP-1 research compound catalog or contact us for custom quantities.